Replies to post #265 on Marinus Pharmaceuticals Inc (MRNS)

[UFO]

Sage Surges on Post-Partum Depression Data, Marinus Follows
By Cristin Flanagan
(Bloomberg) -- Sage Therapeutics jumps as much as 69% to $105.88 in pre-market trading after a key late-stage study in post-partum depression met its main goal. Marinus Pharmaceuticals, which recently announced plans to start a mid-stage trial in the same setting, climbs 33%.
NOTE: Another study of SAGE’s brexanolone in super-refractory status epilepticus (SRSE) failed to meet goals in Sept., raising the stakesfor today’s study to be successful, BofAML said at the time
“We expect shares to move up significantly on this data and for investors to start focusing on the major depressive disorder next,” Suntrust analyst Edward Nash writes in client note this morning; conservatively models $400m for I.V. brexanolone in PPD in 2026, an oral version may generate another $668m
MRNS is studying ganaxolone in PPD as well as SRSE, expects data from Phase 2 studies next year
NOTE: SAGE call 8am, 866-450-8683 pw 7592007
MRNS US Equity
Graphic Dashboard»
SAGE US Equity
Graphic Dashboard»
Related tickers: